Catalent Pharma Solutions, a global company enabling biopharma, cell, gene and consumer health partners to optimize development, launch and supply of patient treatments, will expand its biologics manufacturing operations in Bloomington, Indiana. The $350 million project is expected to create more than 2,300 jobs by the end of 2023.

The 1,000,000-square-foot biologics development and manufacturing facility specializes in sterile formulation and extensive biomanufacturing and drug product fill/finish capacity across liquid and lyophilized vials, prefilled syringes and cartridges.

"Our continued growth in Bloomington demonstrates how important this site has become to the production of medicines for patients worldwide,” said John Chiminski, Chair and CEO at Catalent. “We are immensely grateful for our close collaboration with the state of Indiana, the city of Bloomington, and state and local economic development organizations. The talented, diverse Hoosier workforce and the ambitious business environment provide a strong foundation for our long-term presence in Bloomington."

The Indiana Economic Development Corporation (IEDC) has committed an investment in Catalent of up to $40 million in the form of incentive-based tax credits and up to $2.5 million in conditional training grants based on the company’s job creation plans. The IEDC also committed an additional investment of up to $1.5 million redevelopment tax credits based on the company's investment plans. These tax credits are performance-based, meaning the company is eligible to claim incentives once Hoosiers are hired and trained and investments are made. The city of Bloomington offered additional incentives.

The Bloomington Economic Development Corporation (BEDC) has continued to provide strategic, advisory, and logistical support throughout this project.

"Indiana’s vibrant and unique life sciences industry continues to make a tremendous impact on the Hoosier state through its economic strength, contributing more than $79 billion in 2021," said Governor Eric J. Holcomb. "Indiana is making strategic investments in those businesses, like Catalent, to advance smart technologies and processes, and that investment has allowed Indiana to become the second largest exporter of life sciences products in the U.S. and is recognized as a world leader in the industry."

Catalent, Inc. is a multinational corporation headquartered in Somerset, New Jersey. The company is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. Catalent employs more than 14,000 people, including approximately 2,400 scientists and technicians.